Priorities for Research on Neuromodulatory Subcortical Systems in Alzheimer's Disease: Position Paper from the NSS PIA of ISTAART

The neuromodulatory subcortical system (NSS) nuclei are critical hubs for survival, hedonic tone, and homeostasis. Tau-associated NSS degeneration occurs early in Alzheimer's disease (AD) pathogenesis, long before the emergence of pathognomonic memory dysfunction and cortical lesions. Accumulating evidence supports the role of NSS dysfunction and degeneration in the behavioral and neuropsychiatric manifestations featured early in AD. Experimental studies even suggest that AD-associated NSS degeneration drives brain neuroinflammatory status and contributes to disease progression, including the exacerbation of cortical lesions. Given the important pathophysiologic and etiologic roles that involve the NSS in early AD stages, there is an urgent need to expand our understanding of the mechanisms underlying NSS vulnerability and more precisely detail the clinical progression of NSS changes in AD. Here, the NSS Professional Interest Area of the International Society to Advance Alzheimer's Research and Treatment highlights knowledge gaps about NSS within AD and provides recommendations for priorities specific to clinical research, biomarker development, modeling, and intervention. HIGHLIGHTS: Neuromodulatory nuclei degenerate in early Alzheimer's disease pathological stages. Alzheimer's pathophysiology is exacerbated by neuromodulatory nuclei degeneration. Neuromodulatory nuclei degeneration drives neuropsychiatric symptoms in dementia. Biomarkers of neuromodulatory integrity would be value-creating for dementia care. Neuromodulatory nuclei present strategic prospects for disease-modifying therapies.

Citing Articles

Probing locus coeruleus functional network in healthy aging and its association with Alzheimer's disease biomarkers using pupillometry.

Wu J, Toporek A, Lin Q, Goldstein F, Loring D, Kelberman M Alzheimers Res Ther. 2025; 17(1):53.

PMID: 40016783 PMC: 11866666. DOI: 10.1186/s13195-025-01701-1.

CSF biomarkers are differentially linked to brain areas high and low in noradrenaline, dopamine and serotonin across the Alzheimer's disease spectrum.

Haag L, Lancini E, Yakupov R, Ziegler G, Yi Y, Lusebrink F Brain Commun. 2025; 7(1):fcaf031.

PMID: 39926613 PMC: 11806415. DOI: 10.1093/braincomms/fcaf031.

Stimulate to Remember? The Effects of Short Burst of Transcutaneous Vagus Nerve Stimulation (taVNS) on Memory Performance and Pupil Dilation.

Ludwig M, Betts M, Hammerer D Psychophysiology. 2025; 62(1):e14753.

PMID: 39815765 PMC: 11736245. DOI: 10.1111/psyp.14753.

Resting-State EEG Alpha Rhythms Are Related to CSF Tau Biomarkers in Prodromal Alzheimer's Disease.

Percio C, Lizio R, Lopez S, Noce G, Carpi M, Jakhar D Int J Mol Sci. 2025; 26(1.

PMID: 39796211 PMC: 11720070. DOI: 10.3390/ijms26010356.

Locus coeruleus MRI contrast, cerebral perfusion, and plasma Alzheimer's disease biomarkers in older adults.

Dutt S, Bachman S, Dahl M, Li Y, Yew B, Jang J Neurobiol Aging. 2024; 147:12-21.

PMID: 39637519 PMC: 11781958. DOI: 10.1016/j.neurobiolaging.2024.11.008.

References

Zweig R, Ross C, Hedreen J, Steele C, Cardillo J, Whitehouse P . The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol. 1988; 24(2):233-42. DOI: 10.1002/ana.410240210. View

Grinberg L, Rueb U, Di Lorenzo Alho A, Heinsen H . Brainstem pathology and non-motor symptoms in PD. J Neurol Sci. 2009; 289(1-2):81-8. DOI: 10.1016/j.jns.2009.08.021. View

Betts M, Cardenas-Blanco A, Kanowski M, Spottke A, Teipel S, Kilimann I . Locus coeruleus MRI contrast is reduced in Alzheimer's disease dementia and correlates with CSF Aβ levels. Alzheimers Dement (Amst). 2019; 11:281-285. PMC: 6439222. DOI: 10.1016/j.dadm.2019.02.001. View

Liguori C, Placidi F, Izzi F, Spanetta M, Mercuri N, Di Pucchio A . Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer's disease course. Alzheimers Res Ther. 2020; 12(1):5. PMC: 6942389. DOI: 10.1186/s13195-019-0571-3. View

Feng C, Wiggins L, von Bartheld C . The locus ceruleus responds to signaling molecules obtained from the CSF by transfer through tanycytes. J Neurosci. 2011; 31(25):9147-58. PMC: 4050199. DOI: 10.1523/JNEUROSCI.5018-10.2011. View

Chen Y, Shu K, Kang H . Deep Brain Stimulation in Alzheimer's Disease: Targeting the Nucleus Basalis of Meynert. J Alzheimers Dis. 2021; 80(1):53-70. DOI: 10.3233/JAD-201141. View

Liu K, Kievit R, Tsvetanov K, Betts M, Duzel E, Rowe J . Noradrenergic-dependent functions are associated with age-related locus coeruleus signal intensity differences. Nat Commun. 2020; 11(1):1712. PMC: 7136271. DOI: 10.1038/s41467-020-15410-w. View

Keute M, Wienke C, Ruhnau P, Zaehle T . Effects of transcutaneous vagus nerve stimulation (tVNS) on beta and gamma brain oscillations. Cortex. 2021; 140:222-231. DOI: 10.1016/j.cortex.2021.04.004. View

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

10.

Ludtke S, Hermann W, Kirste T, Benes H, Teipel S . An algorithm for actigraphy-based sleep/wake scoring: Comparison with polysomnography. Clin Neurophysiol. 2020; 132(1):137-145. DOI: 10.1016/j.clinph.2020.10.019. View

11.

Li S, Lindenberger U, Sikstrom S . Aging cognition: from neuromodulation to representation. Trends Cogn Sci. 2001; 5(11):479-486. DOI: 10.1016/s1364-6613(00)01769-1. View

12.

Kovalevich J, Langford D . Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol. 2013; 1078:9-21. PMC: 5127451. DOI: 10.1007/978-1-62703-640-5_2. View

13.

Braver T, Barch D . A theory of cognitive control, aging cognition, and neuromodulation. Neurosci Biobehav Rev. 2002; 26(7):809-17. DOI: 10.1016/s0149-7634(02)00067-2. View

14.

Jessen F, Amariglio R, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G . A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014; 10(6):844-52. PMC: 4317324. DOI: 10.1016/j.jalz.2014.01.001. View

15.

Bachman S, Cole S, Yoo H, Nashiro K, Min J, Mercer N . Daily heart rate variability biofeedback training decreases locus coeruleus MRI contrast in younger adults in a randomized clinical trial. Int J Psychophysiol. 2023; 193:112241. PMC: 10591988. DOI: 10.1016/j.ijpsycho.2023.08.014. View

16.

Jacobs H, Priovoulos N, Poser B, Pagen L, Ivanov D, Verhey F . Dynamic behavior of the locus coeruleus during arousal-related memory processing in a multi-modal 7T fMRI paradigm. Elife. 2020; 9. PMC: 7343392. DOI: 10.7554/eLife.52059. View

17.

Bernard R, Kerman I, Thompson R, Jones E, Bunney W, Barchas J . Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry. 2010; 16(6):634-46. PMC: 2927798. DOI: 10.1038/mp.2010.44. View

18.

Ma P . Catecholaminergic systems in the zebrafish. II. Projection pathways and pattern of termination of the locus coeruleus. J Comp Neurol. 1994; 344(2):256-69. DOI: 10.1002/cne.903440207. View

19.

Chamberlain S, Robbins T . Noradrenergic modulation of cognition: therapeutic implications. J Psychopharmacol. 2013; 27(8):694-718. DOI: 10.1177/0269881113480988. View

20.

Cohen R, Rezai-Zadeh K, Weitz T, Rentsendorj A, Gate D, Spivak I . A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci. 2013; 33(15):6245-56. PMC: 3720142. DOI: 10.1523/JNEUROSCI.3672-12.2013. View